title: Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.
abstract: Duchenne muscular dystrophy (DMD) is an X-linked human disorder in which absence of the protein dystrophin causes degeneration of skeletal and cardiac muscle. For the sake of treatment development, over and above definitive genetic and cell-based therapies, there is considerable interest in drugs that target downstream disease mechanisms. Drug candidates have typically been chosen based on the nature of pathologic lesions and presumed underlying mechanisms and then tested in animal models. Mammalian dystrophinopathies have been characterized in mice (mdx mouse) and dogs (golden retriever muscular dystrophy [GRMD]). Despite promising results in the mdx mouse, some therapies have not shown efficacy in DMD. Although the GRMD model offers a higher hurdle for translation, dogs have primarily been used to test genetic and cellular therapies where there is greater risk. Failed translation of animal studies to DMD raises questions about the propriety of methods and models used to identify drug targets and test efficacy of pharmacologic intervention. The mdx mouse and GRMD dog are genetically homologous to DMD but not necessarily analogous. Subcellular species differences are undoubtedly magnified at the whole-body level in clinical trials. This problem is compounded by disparate cultures in clinical trials and preclinical studies, pointing to a need for greater rigor and transparency in animal experiments. Molecular assays such as mRNA arrays and genome-wide association studies allow identification of genetic drug targets more closely tied to disease pathogenesis. Genes in which polymorphisms have been directly linked to DMD disease progression, as with osteopontin, are particularly attractive targets.
authors.forename: Joe N
authors.initials: JN
authors.lastname: Kornegay
authors.forename: Christopher F
authors.initials: CF
authors.lastname: Spurney
authors.forename: Peter P
authors.initials: PP
authors.lastname: Nghiem
authors.forename: Candice L
authors.initials: CL
authors.lastname: Brinkmeyer-Langford
authors.forename: Eric P
authors.initials: EP
authors.lastname: Hoffman
authors.forename: Kanneboyina
authors.initials: K
authors.lastname: Nagaraju
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D016503:Drug Delivery Systems / Q000379:methods*; D055808:Drug Discovery / Q000331:legislation & jurisprudence / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D051379:Mice; D018101:Mice, Inbred mdx; D020388:Muscular Dystrophy, Duchenne / Q000188:drug therapy* / Q000503:physiopathology*; D010597:Pharmacogenetics / Q000379:methods*; D013045:Species Specificity; D057170:Translational Research, Biomedical / Q000379:methods
keywords: Duchenne muscular dystrophy; animal models; drug development; genome wide association studies; golden retriever muscular dystrophy; mRNA arrays; mdx mouse; preclinical studies